BioCryst Pharma (BCRX) Reports Q4 Loss of $0.40/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones
February 23, 2022 7:00 AM ESTQ4 2021 ORLADEYO net revenue of $46.2 million and $122.6 million for FY 2021
ORLADEYO net revenue in 2022 expected to be no less than $250 million
Pivotal trials in PNH and proof-of-concept trial in three renal indications currently enrolling patients
RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... More
